Loading company
Tessera Defense & Homeland Security Inc.
HLSQ · NYSE · ·
Next earnings: November 11, 2026
$0.43-7.7%Sep 29 close
- 1M
- -68.9%
- 6M
- -99.0%
- 1Y
- -99.6%
- 5Y
- -100.0%
HLSQ · NYSE · ·
Next earnings: November 11, 2026
$0.43-7.7%Sep 29 close
Tessera Defense & Homeland Security Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$3.8M | -$6M | +36.29% |
| Profit per share | -$0.37 | -$0.33 | -12.49% |
| Free Cash Flow | -$4.4M | -$6M | +26.34% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tessera Defense & Homeland Security Inc. has no earnings call transcript available.
“This past quarter was defined by significant advancements in our regulatory discussions with the Food and Drug Administration (FDA) across our pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa , a main contributor to morbidity and mortality in patients with CF. In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial where BX004 demonstrated improvement in pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function (baseline FEV1<70%). Pending resolution of the clinical hold imposed by the FDA, BiomX expects to enroll up to approximately 60 patients in a randomized, double blind, placebo-controlled, multi-center Phase 2b trial of BX004 in CF patients with chronic P. aeruginosa lung infections. The 8-week study will assess lung function, bacterial load, and quality of life metrics. BX004 has received FDA Fast Track and Orphan Drug Designations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tessera Defense & Homeland Security Inc.’s Item 2.02 8-K filed November 12, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.